Biomedicine Daily · Saturday, 10 October 2026
CBA FRONTIER INSIGHTS
Two B7-H3 ADCs Post Identical 0.46 Survival Hazard Ratios in Relapsed Small Cell Lung Cancer
Two B7-H3 antibody-drug conjugates delivered Phase III overall survival wins in relapsed small cell lung cancer at the September 2026 WCLC presidential forum in Seoul. Tambotatug pelitecan (YL-201, MediLink Therapeutics) in TAISHAN-302 and risvutatug rezetecan (HS-20093, Hansoh/GSK) in ARTEMIS-008 each hit an overall survival hazard ratio of 0.46, rewriting a second-line standard that had held for three decades and putting B7-H3 ADCs in direct contention with DLL3 bispecifics in the same setting. The day also brought a negative Phase 3 for nicotinamide riboside in early Parkinson disease (MDS-UPDRS worsening of 2.72 points vs placebo, P = .02), FDA approval of pritelivir for acyclovir-resistant herpes lesions, and Kodiak's dual Phase III DAYBREAK success in ophthalmology.
Clinical readouts and safety
Two B7-H3 ADCs Post Phase III OS Wins With Hazard Ratio 0.46 in Relapsed Small Cell Lung Cancer
Two B7-H3 antibody-drug conjugates delivered Phase III overall survival wins in relapsed small cell lung cancer at the September 2026 WCLC presidential forum in Seoul. Tambotatug pelitecan (YL-201, from MediLink Therapeutics) in TAISHAN-302 and risvutatug rezetecan (HS-20093, from Hansoh/GSK) in ARTEMIS-008 each hit an overall survival hazard ratio of 0.46, rewriting a second-line standard that had held for three decades and putting B7-H3 ADCs in direct contention with DLL3 bispecifics in the same setting.
medicalxpress.comCervical cancer trial finds similar early recovery results after robot-assisted versus open surgery
Robot-assisted radical hysterectomy for early-stage cervical cancer produced fewer intraoperative complications than open surgery (5.7% vs 10.0%), but the difference mainly involved less serious events. In the randomized RACC study of 900 patients across European hospitals, complications within 30 days were nearly identical (33.4% vs 34.8%), and overall early recovery and most quality-of-life measures were similar. Recurrence-free survival, the primary outcome, is still being followed.
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
Nicotinamide riboside, 500 mg twice daily for 52 weeks, did not improve clinical outcomes in early Parkinson disease and was worse than placebo. In the phase 3 NOPARK trial of 393 patients, the MDS-UPDRS parts I-III score worsened by 2.72 points with nicotinamide riboside relative to placebo (P = .02), and nonmotor symptom burden worsened more on treatment (NMSS difference 4.22 points, P = .009). The findings do not support nicotinamide riboside as a disease-modifying treatment.
Kodiak Sciences' Zenkuda and Tabirafusp-ted Hit Primary Endpoint in Phase III DAYBREAK Trial
Kodiak Sciences reported on September 28, 2026 that its two ophthalmology drug candidates, Zenkuda and tabirafusp-ted, both met the primary endpoint in the pivotal Phase III DAYBREAK study, which compared the ABC fusion candidates against aflibercept. The company plans to submit Zenkuda for market approval in the fourth quarter of 2026. The results position the lead candidate for regulatory filing.
Oral GLP-1 Agonist Safiglipron Improves Glycemic Control in Phase 3 OUTSTAND-1 Trial
The oral small-molecule GLP-1 receptor agonist safiglipron (HRS-7535), developed by Hengrui Pharmaceuticals and taken once daily without fasting or dietary restrictions, significantly improved glycemic control as monotherapy in patients with early type 2 diabetes in the phase 3 OUTSTAND-1 trial. Higher doses also produced weight benefits, and improvements were observed in islet function and multiple cardiometabolic and cardiorenal metabolic markers. The results were published in Nature Medicine.
[Articles] Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial
In the TOSYMA randomised trial, screening with digital breast tomosynthesis plus synthesised 2D mammography avoided roughly a quarter of invasive interval breast cancers over 24 months compared with digital mammography alone. The primary outcome did not reach statistical significance. The trial adds evidence supporting tomosynthesis plus s2D in breast cancer screening.
Gene Therapy Restores Partial Sight in Clinical Trial
An optogenetic therapy partially restored vision in a clinical trial of patients with retinitis pigmentosa, as reported by Sahel and colleagues in Nature Medicine in 2021. The approach delivers a gene for a light-sensitive protein and pairs it with specialized goggles, and visual recovery was observed in an individual participant in this early, small trial. The work is from 2021 and not a new advance.
Regulatory and policy
FDA Approves Drug to Treat Lesions Caused by Herpes Simplex Virus
FDA has approved Hovilpri (pritelivir) tablets for immunocompromised adults with mucocutaneous herpes simplex virus lesions who did not respond to acyclovir, valacyclovir or famciclovir. In the Phase 3 PRIOH-1 Part C trial of 101 adults, all lesions healed within 28 days in 63% of pritelivir patients versus 34% on investigator-chosen treatments. The drug received priority review, and headache was the most common adverse reaction.
NMPA Approves Beijing Bailian Medical's Transcatheter Pulmonary Valve System
China's National Medical Products Administration has approved the innovative device registration application for the transcatheter pulmonary valve system of Beijing Bailian Medical Technology. The system, comprising a delivery system with a delivery catheter and loader, is placed via a small transthoracic incision. It is indicated for patients aged at least 9 years and weighing at least 20 kg with severe pulmonary regurgitation and a native right ventricular outflow tract after surgery for complex congenital heart disease.
HHS launches new plan to strengthen vaccine injury research, reporting
HHS, under Secretary Robert F. Kennedy Jr., announced a plan to strengthen surveillance of vaccine-related injuries, including a new NIH clinic in Bethesda, Md. opened Oct. 5 to investigate health problems following vaccination. HHS will also pay doctors for reporting suspected side effects to VAERS, update the system, and require electronic health records to capture vaccine-related adverse events. Experts such as Paul Offit of Children's Hospital of Philadelphia argue the moves could further weaken confidence in vaccines.
Industry and deals
TRex Bio prices $117M IPO to support immune drug work
TRex Bio priced a $117 million IPO, selling 8,333,334 shares at $14 each, and begins trading Friday on Nasdaq under "TRXB." The company is developing Treg-activating drugs for immunological conditions, including TRB-061, in a Phase 1 trial with topline data expected in 2027, and TRB-071 for inflammatory bowel disease, which could enter testing next year. Eli Lilly, TRex's largest equity holder at about 24% pre-IPO, and Johnson & Johnson have licensed or optioned treatments discovered by TRex, which has raised $220 million in venture financing to date.
news.google.comOno pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset - Fierce Biotech
TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
TRexBio raised $116.7 million in its Nasdaq IPO, selling 8.3 million shares at $14 to fund TRB-061, a fusion protein in early-stage development for atopic dermatitis with a Phase 1b topline readout expected mid-2027. Retension Pharmaceuticals raised $45 million at $12 per share to advance RTN-001, a PDE-5 blocker for hypertension, through Phase 2b and into Phase 3. City Therapeutics expects about $158.3 million and Iambic Therapeutics about $135 million from upcoming offerings.
biocentury.comMatchpoint’s $150M tops the week’s private rounds: Venture Report
Matchpoint Therapeutics, a Watertown, Mass.-based biotech, raised a $150 million series B to take its lead program to proof of concept, four years after a $100 million series A. It was one of at least four companies closing venture rounds of at least $25 million in the past week, while European VC Forbion raised a record €2.3 billion in new funds.
Research papers
DNA Typewriter Reconstructs Mouse Cell Lineage Tree from Zygote to E13.5
A DNA Typewriter recorded cell lineage in a living mouse, and from a single embryo the team reconstructed a phylogenetic tree rooted at the zygote, time-calibrated to E13.5, containing 1.28 million cells annotated with transcriptomes. The work, by Chengxiang Qiu with Jay Shendure's group at the University of Washington, published in Science on October 9, 2026, closes a 50-year gap since Sulston manually traced a nematode's cell divisions. The tree reveals clonal dominance during gastrulation, hierarchical structure coupled to cell type, and ancestral state paths.
Message in a bottleneck: Nested founder effects from French Polynesia to Rapa Nui and Hawai'i.
Polynesians experienced founder effects an order of magnitude stronger than those described in European-descent groups such as the Finnish and Amish during their settlement of Eastern Polynesia. Whole-genome sequences spanning Polynesia show that Hawai'i and Rapa Nui, the two most bottlenecked populations, were likely settled by the same ultravoyagers with ancestral roots in Mangareva. The analysis identifies a loss-of-function FAN1 mutation common in Eastern Polynesia (>1%) but absent from gnomAD, offering a target for population-specific genetic testing.
medicalxpress.comAncient viral DNA helps embryonic stem cells grow—and cancer hijacks the same switch
A human endogenous retrovirus, HERVH, drives production of the calcium-buffering protein calbindin in embryonic stem cells, and the same pathway had earlier been seen helping cancer cells survive by preventing them from aging. Editing human embryonic stem cells to remove the HERVH switch left cells unhealthy, failing to grow or specializing prematurely, and blastoids and post-gastrulation amnioids lacking HERVH-driven calbindin could not form properly. Primate genome comparisons place the HERVH integration after the split from orangutans, roughly 13 million years ago.
Mitigating lateral sensing blind spots: A dual-segment bronchoscopic robot with a bioinspired skin.
A dual-segment bronchoscopic robot wrapped with a snake-scale-inspired 64-channel gradient piezoelectric film resolves lateral force blind spots during robotic bronchoscopy. The sensor detects force in under 10 ms with R2 > 0.98 and RMSE < 0.145 N, and filters bending pseudo-forces. In phantom and ex vivo porcine lung tests it localized contact in real time, triggered alarms at 5.0 N, and autonomously tuned contact forces below 3.0 N.
medicalxpress.comDistinct malaria parasites may help explain sickle cell trait's protection against disease
People with the sickle cell variant are infected by genetically distinct malaria parasites and are a tenth as likely to develop symptomatic disease, according to sequencing of more than 2,000 people in Mfou, Cameroon, and the parasites infecting them. Asymptomatic infections affected three-quarters of the healthy study population, and parasite varieties differed by sickle cell status. The finding shifts explanation of sickle cell trait's protection toward the parasite genotype, not only the host response.
medicalxpress.comElectrical ablation boosts CAR-NK cell therapy against liver cancer, offering new strategy for refractory solid tumors
Irreversible electroporation (IRE) combined with GPC3-targeted CAR-NK cells, made with lipid nanoparticle gene delivery, produced substantially stronger tumor control than either treatment alone in hepatocellular carcinoma. IRE reshaped the immunosuppressive tumor microenvironment: chemokine levels rose, recruiting NK cells early, while IRE-induced reactive oxygen species left residual tumor cells more susceptible to NK cell killing. Across multiple preclinical models the combination showed superior tumor suppression and prolonged survival.
Oligo(uridine) tailing and exonucleolytic decay drive 40S ribosome degradation in response to stress
Stress-induced degradation of 40S ribosomes proceeds through 3′ oligo(U) tailing of 18S rRNA. TUT7 is recruited to ubiquitylated 40S ribosomes and uridylates the 18S rRNA, and iterative uridylation followed by 3′-5′ decay by the exonuclease DIS3L2 drives degradation of the 18S rRNA and the 40S ribosome. The work identifies the enzymatic route linking ribosome ubiquitylation to decay.
The Red Blood Cell Surface Defines a Distinct Tumor DNA Compartment for Liquid Biopsy
Red blood cells tether and retain tumor-derived DNA on their surface, forming a distinct circulating pool of RBC-bound tumor DNA (rtDNA), with desialylation increasing capture in a Toll-like receptor 9-dependent manner. In mice bearing lung cancer xenografts, rtDNA was detected in all animals and tracked tumor burden while plasma tumor DNA was undetectable; in patients with lung cancer, most detected mutant tumor DNA was RBC-associated and concordant with matched tumor tissue. The findings challenge the plasma-centric liquid biopsy paradigm by identifying the RBC surface as a tunable reservoir of tumor DNA.
medicalxpress.comScientists identify the neuroblastoma cells that signal poor outcomes
A gene expression signature distinguishes malignant mesenchymal neuroblastoma cells, the population linked to high-risk disease and treatment resistance, from healthy mesenchymal cells that had confounded earlier efforts. Built from 54 tumors across 50 patients using single-cell RNA sequencing and spatial omics, the signature improved outcome predictions in an independent tumor database, where a signature from decades-old cell lines did not. Patient-derived xenografts, organoids and new cell lines capturing both cell states are available through the St. Jude Childhood Solid Tumor Network.
medicalxpress.comCurrent age-based genetic testing in patients with cancer may miss the majority of inherited gene variants
Universal germline testing of 39,184 patients with solid tumors found germline pathogenic variants in 16.3% overall, and restricting testing to patients under age 50 would have excluded 4,601 carriers, or 72% of all patients with pathogenic variants. Even with cancer type-specific onset definitions, pathogenic variants appeared in 12.3% of late-onset cancers. The findings support germline genetic testing for every patient with cancer regardless of age at diagnosis.
medicalxpress.comScientists uncover two-pronged strategy to overcome glioblastoma's resistance to immunotherapy
Combining low-dose axitinib to relieve tumor hypoxia with a 4-1BB agonist overcame glioblastoma's resistance to immunotherapy in mouse models, shrinking tumors and preventing regrowth. Axitinib alone extended median survival modestly, from 17 to 19 days, but the combination reached 42 days with a 40% long-term survival rate, and surviving mice resisted tumor re-challenge, indicating immune memory.
A mitotic restriction point for extrachromosomal DNA hubs in cancer cells
Mitosis is the critical window in which extrachromosomal DNA (ecDNA) hubs are organised and inherited across cell generations. An optical screen identified the mitotic-entry regulator WEE1 as a key regulator of hub integrity and oncogene expression, with CDK1- and CDK2-regulated programmes cooperating to carry unresolved damage into mitosis and reorganise ecDNA tethered to mitotic chromosomes. Live-cell imaging shows hub architecture is remodelled during mitosis and maintained through interphase, a coupling conserved across cancer types and ecDNA-associated oncogenes, defining a mitotic restriction point and a potential therapeutic window for ecDNA-driven cancers.
40S ribosome remodeling triggers 18S rRNA U-tailing and DIS3L2-dependent decay
RIOK3 remodels ubiquitinated 40S ribosomal subunits so that the 3′ end of 18S rRNA is exposed and uridylated, marking it for DIS3L2-mediated degradation. The finding couples ribosomal protein ubiquitination triggered by translational perturbations to selective 18S rRNA turnover, filling a gap in how 40S ribosome quality control is executed.
Methods and resources
Mapping transcriptional responses to cellular perturbations with RNA fingerprinting
Random mtDNA mutagenesis maps genotype-phenotype associations across metabolic contexts and lineages
mtDIVE, a random C→T mutagenesis platform, enables pooled mitochondrial forward genetics in human epithelial cells and zebrafish embryos, generating molecules from single substitutions to more than 100 mutations. Selection on mutant genomes and their transcriptional consequences depend on metabolic state and developmental lineage: obligate OXPHOS eliminates highly mutated cells by apoptosis, while glycolytic conditions promote their competitive displacement. Individual loci have modest, non-redundant effects that predict cell state beyond mutation burden, and cancer-recurrent variants are enriched among mutations linked to reduced mitochondrial transcription.
Toward transgenic multicellular parasites: CRISPR-Cas12a germline editing of Schistosoma mansoni eggs as key to success.
Cas12a outperformed Cas9 for homology-directed insertion of a 5'-C6-PEG10-modified donor template with 50-nucleotide microhomology arms into the GSH1 safe-harbor site of Schistosoma mansoni eggs. Electroporated eggs expressing EGFP under an S. mansoni ubiquitin promoter yielded transgenic cercariae that produced EGFP-positive adult worms in hamsters. Sequencing confirmed stable chromosomal integration transmitted through filial generations, opening functional genomics in platyhelminths.
Systematic mapping of enhancers, silencers, and topological elements with prime editing deletion screens
Swap-seq, a method combining pooled twin prime editing with flow-sorting, deletes hundreds of endogenous regulatory sequences and measures their quantitative effects on nearby gene expression. Applied to PPIF regulation in THP-1 monocytes, it quantifies distal and intronic enhancers, characterizes CTCF insulators, and uncovers a silencer that represses neighboring enhancers through HDAC-mediated mechanisms, with hundreds of genomic elements sharing its signatures. The resulting data show sequence-to-function models capture local element activity but fail to link elements to distal target genes.
Opinion and commentary
youtube.comJames Kirkland presents senolytics and cell-clearing strategies at CSHL lecture
James Kirkland outlined senolytics, agents that selectively clear tissue-damaging senescent cells, in a Cold Spring Harbor Laboratory aging symposium talk. He traced the field's discovery logic to an analogy with the death-resistance of leukemia and lymphoma cells, which led to screening natural products and repurposed drugs that briefly switch off senescent cell defenses. He said cancer settings need a new class of senolytics or "senescent sensitizers" to remove senescent cells that may carry cancer-causing mutations, and that several agents have entered clinical trials.
youtube.comGeraldine Seydoux Reviews Germline Establishment and mRNA Condensates in C. elegans at CSHL
Geraldine Seydoux delivered a 2025 CSHL Leading Strand lecture on how asymmetric divisions in the early invariant C. elegans lineage separate germline from somatic fate. She discussed cytoplasmic condensates such as P-granules in mRNA decay and translational control, and described intrinsically disordered proteins that coat and stabilize RNA granule surfaces, an intracellular Pickering emulsifier mechanism. The talk links post-transcriptional regulation, condensate physics and developmental fate decisions.
Also today
21 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
RegulatoryChina NMPA Approves Dato · FDA Approves Bristol Myers Squibb's Mavacamten for Symptomatic Obstructive HCM in Patients Weighing · Juvmo (tavapadon) · Tukysa …8 ▾▴
Filings, acceptances, designations, approvals and withdrawals at a regulator.
- China NMPA Approves DatoUpdateChina's NMPA approved datopotamab deruxtecan (Dato-DXd) on September 29, 2026 for adults with unresectable or metastatic triple-negative breast cancer who are not suitable for PD-1/PD-L1 inhibitor treatment. It is the first and only TROP2-targeting ADC approved for this indication with an overall survival benefit, and it marks Dato-DXd's second breast cancer approval in China after HR-positive, HER2-negative advanced breast cancer.NMPA
- FDA Approves Bristol Myers Squibb's Mavacamten for Symptomatic Obstructive HCM in Patients Weighing UpdateThe FDA has approved Bristol Myers Squibb's mavacamten to improve functional capacity and symptoms in children and adults weighing 30 kg (66 lb) or more who have symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval is based on positive results from the Phase 3 SCOUT-HCM trial and extends the drug's existing clinical evidence in adult oHCM. Mavacamten is the only FDA-approved drug for pediatric oHCM.FDA
- Juvmo (tavapadon)UpdateThe FDA has approved AbbVie's D1/D5 receptor partial agonist Juvmo (tavapadon) for the treatment of Parkinson's disease in adults. The approval adds a new option that works by selectively modulating D1/D5 receptors, a subclass of dopamine receptors identified as a potential Parkinson's target more than 30 years ago, though progress on the approach had been slow. Juvmo becomes a newly approved choice for adult patients.FDA
- TukysaUpdateFDA
- FDA Approves IV and Subcutaneous Tecentriq for Stage III dMMR Colon Cancer Adjuvant TherapyUpdateOn October 8, 2026, the FDA approved Genentech/Roche's atezolizumab (Tecentriq), given intravenously with fluoropyrimidine plus oxaliplatin chemotherapy, as adjuvant treatment after surgery for stage III mismatch repair-deficient (dMMR) colon cancer in adults and children aged 2 and older. The subcutaneous formulation Tecentriq Hybreza, atezolizumab with hyaluronidase-tqjs, was also approved with the same chemotherapy for patients aged 12 or older weighing at least 40 kg. These are Tecentriq's second US indication expansions this year, after its approval months earlier for Signatera ctDNA-positive muscle-invasive bladder cancer.FDA
- NMPA Approves Enhertu for Adjuvant Treatment of HER2UpdateChina's NMPA approved on September 29, 2026 Enhertu (trastuzumab deruxtecan), jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, as adjuvant treatment for adults with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane plus trastuzumab-based therapy. The approval rests on the DESTINY-Breast05 phase III trial, presented at ESMO 2025 and published in the New England Journal of Medicine. It is Enhertu's ninth approved indication in China, six of them in breast cancer.NMPA
- Gan & Lee's Insulin Aspart Becomes First Biosimilar of Its Kind Approved in EthiopiaUpdateGan & Lee Pharmaceuticals has received registration approval from the Ethiopian Food and Drug Authority for its insulin aspart injection, the first insulin aspart biosimilar approved in Ethiopia. The approval follows the January 2026 launch of its insulin glargine injection in the country, giving the company two core insulin products approved there within one year as it builds its pipeline in sub-Saharan Africa, where diabetes prevalence keeps rising.
- HEC Pharm Wins NMPA Approval for DegludecUpdateChina's NMPA approved HEC Pharm's degludec/insulin aspart co-formulation injection, a Class 3.3 new drug, for type 2 diabetes, with the approval listed on the agency's website on October 8. The premixed dual insulin analogue contains 70% insulin degludec and 30% insulin aspart. Sales of degludec/insulin aspart injections across China's three major terminals and six markets reached nearly 3 billion yuan in 2025 and grew 10.28% year-on-year in the first half of 2026.NMPA
ClinicalOral deucrictibant for on · Argenx Stops Phase III UNITY Trial of Subcutaneous Efgartigimod in Sjögren's Syndrome · Argenx Vyvgart · STAT+ …5 ▾▴
Trial starts, early and mid-stage data, and results that did not make the daily.
- Oral deucrictibant for onUpdateA 20 mg oral deucrictibant capsule gave faster onset of symptom relief than placebo in hereditary angioedema attacks, with median relief times of under one and a half hours for deucrictibant and beyond twelve hours for placebo, a statistically significant difference. In the phase 3 RAPIDe-3 crossover trial, 113 participants treated 201 attacks, and no severe, serious or treatment-related discontinuation events occurred. Deucrictibant could become the first orally administered bradykinin B2 receptor antagonist for treating attacks of bradykinin-mediated angioedema.
- Argenx Stops Phase III UNITY Trial of Subcutaneous Efgartigimod in Sjögren's SyndromeUpdateArgenx has terminated the Phase III UNITY trial of subcutaneous efgartigimod (Vyvgart Hytrulo) in moderate-to-severe Sjögren's syndrome after an interim futility analysis by an independent data monitoring committee showed the study would not meet its primary endpoint. The decision weakens expectations for expanding Vyvgart into a new indication, and argenx shares fell 13.73% premarket on the news.
- Argenx VyvgartUpdate
- STAT+Update
- Prula-celUpdate
Deals and financingHow Abogen went from COVID hype to a $7.8B Novartis deal · Novo Nordisk Licenses Hengrui's Once · Viatris ← Pacira · Roche Signs Multi …7 ▾▴
Licensing, M&A and financing that did not make the daily.
- How Abogen went from COVID hype to a $7.8B Novartis dealUpdateNovartis has taken an exclusive worldwide license to ABO2203, Abogen Biosciences' mRNA-encoded CD19xCD3 T cell engager for B-cell malignancies and autoimmune diseases, paying $575 million upfront with up to roughly $7.2 billion in potential option, milestone and royalty payments. Early data in relapsed or refractory B-cell non-Hodgkin lymphoma showed overall response rates of 33%, 67% and 100% across dose cohorts, with no CRS or ICANS reported. The deal, which also gives Novartis options on further Abogen RNA platform programs, marks Abogen's shift beyond its faded COVID vaccine business.
- Novo Nordisk Licenses Hengrui's OnceUpdateNovo Nordisk has licensed HRS-1596, a once-weekly oral GLP-1 from Hengrui Pharmaceuticals, in a global licence deal announced on September 29. Novo Nordisk gains development, manufacturing and commercialisation rights outside mainland China, Hong Kong, Macau and Taiwan. The deal is valued at $300 million, and HRS-1596 is positioned as a potential challenger to tirzepatide.
- Viatris ← PaciraUpdateViatris has agreed to buy Pacira BioSciences for $1.65 billion, or $36.50 per share in cash, to build a non-opioid pain therapy business. The deal adds Exparel, a post-surgical injectable bupivacaine, and Zilretta, an injectable corticosteroid for osteoarthritis knee pain, which generated sales of $587 million and $121 million respectively in the second half of 2025 and first half of this year. Viatris expects to close the takeover by the end of the year, while the FDA is due to rule on its fast-acting meloxicam filing for moderate-to-severe acute pain by Dec. 27.
- Roche Signs MultiUpdateOn October 8, a biotech focused on molecular glue degrader drugs announced a research collaboration and licensing agreement with Roche to discover and develop new molecular glue degraders against multiple targets in oncology and immunology. The biotech will apply its proprietary platform to find degraders for specified therapeutic targets; once projects reach defined research stages, Roche takes over preclinical and clinical development and holds exclusive worldwide commercialization rights.
- Ultragenyx Sells Third Priority Review Voucher for $210 Million After Genglycos ApprovalUpdateUltragenyx has sold a rare pediatric disease priority review voucher for $210 million to an undisclosed buyer. The voucher was earned through FDA approval of Genglycos, its gene therapy for glycogen storage disease type Ia. The company previously sold its first two vouchers in 2018 for a combined $210.6 million.
- IambicUpdate
- Melissa explains it all in menopause team up with BayerUpdate
OtherBrevital Sodium 500 mg/vial1 ▾▴
Everything else with a concrete event that did not make the daily.
- Brevital Sodium 500 mg/vialUpdatePar Health is voluntarily recalling two lots of Brevital Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP), distributed by Par Pharmaceutical, to the hospital level because of particulate matter identified as cellulose. Lots 86930 (exp. 02/2028) and 88623 (exp. 04/2028), item code 42023-105-01, were distributed nationwide to wholesalers between July 8, 2025 and May 11, 2026. No adverse events have been reported; wholesale distributors and hospital pharmacies should stop use and distribution, with returns handled through Inmar, Inc.